FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968314925> ?p ?o ?g. }

• W1968314925 endingPage "130" @default.
• W1968314925 startingPage "125" @default.
• W1968314925 abstract "Background Treatment of patients who have locally advanced non–small-cell lung cancer and compromised performance status or weight loss (WL) is challenging. This study was conducted to test a low toxicity treatment regimen in this cohort. Patients and Methods Patients were treated with concurrent celecoxib and thoracic radiation therapy to 45 Gy in 15 fractions or 60 to 66 Gy in 30 to 33 fractions. Eligible patients had inoperable or unresectable stage IIB, IIIA/B NSCLC, performance status 2 and/or greater than 5% WL. In the phase I portion of the study, the starting dose of celecoxib was 200 mg twice daily with one dose escalation to 400 mg twice daily. Celecoxib was continued for 2 years or until progression. Results The phase I component accrued eight patients each at 200 mg twice daily and 400 mg twice daily. Twice daily 400 mg was chosen for the phase II component, which enrolled five patients and was closed early because of poor accrual. We were able to analyze 18 patients. Performance status ratings were 0, 1, and 2 in 7, 7, and 4 patients, respectively. Median age was 72 years. WL of greater than 5% was noted in 10 patients (56%). Four of 10 had WL greater than or equal to 20%. Median follow-up and survival was 10 months. Overall survival rates at 1 and 2 years were 44.4% [95% confidence interval (CI), 21.6%–65.1%] and 22.2% (95% CI, 6.9%–42.9%), respectively. Progression-free survival at 1 year was 33.3% (95% CI, 13.7%–54.5%). Toxicities matched those expected with thoracic radiotherapy alone. Conclusion Concurrent thoracic radiation therapy and celecoxib was well tolerated. The sample size was too small to draw conclusions regarding efficacy." @default.
• W1968314925 created "2016-06-24" @default.
• W1968314925 creator A5004625690 @default.
• W1968314925 creator A5051894582 @default.
• W1968314925 creator A5052233371 @default.
• W1968314925 creator A5059111432 @default.
• W1968314925 creator A5063411006 @default.
• W1968314925 creator A5064716632 @default.
• W1968314925 creator A5066993165 @default.
• W1968314925 creator A5090256464 @default.
• W1968314925 date "2011-03-01" @default.
• W1968314925 modified "2023-09-27" @default.
• W1968314925 title "Phase I/II Trial of a COX-2 Inhibitor With Limited Field Radiation for Intermediate Prognosis Patients Who Have Locally Advanced Non–Small-Cell Lung Cancer: Radiation Therapy Oncology Group 0213" @default.
• W1968314925 cites W1898736255 @default.
• W1968314925 cites W1912918175 @default.
• W1968314925 cites W1944220675 @default.
• W1968314925 cites W1967974729 @default.
• W1968314925 cites W1968151036 @default.
• W1968314925 cites W1972143153 @default.
• W1968314925 cites W1973641691 @default.
• W1968314925 cites W1997734596 @default.
• W1968314925 cites W2000445173 @default.
• W1968314925 cites W2008778808 @default.
• W1968314925 cites W2011797387 @default.
• W1968314925 cites W2014145691 @default.
• W1968314925 cites W2025578423 @default.
• W1968314925 cites W2033933136 @default.
• W1968314925 cites W2037960143 @default.
• W1968314925 cites W2040755286 @default.
• W1968314925 cites W2047191693 @default.
• W1968314925 cites W2050310941 @default.
• W1968314925 cites W2058841871 @default.
• W1968314925 cites W2062800226 @default.
• W1968314925 cites W2076880391 @default.
• W1968314925 cites W2078765085 @default.
• W1968314925 cites W2082687472 @default.
• W1968314925 cites W2087680614 @default.
• W1968314925 cites W2090558521 @default.
• W1968314925 cites W2105130747 @default.
• W1968314925 cites W2105960398 @default.
• W1968314925 cites W2120850551 @default.
• W1968314925 cites W2131228625 @default.
• W1968314925 cites W2155053061 @default.
• W1968314925 cites W2161917912 @default.
• W1968314925 cites W2163709153 @default.
• W1968314925 cites W2229509524 @default.
• W1968314925 cites W3041047318 @default.
• W1968314925 doi "https://doi.org/10.1016/j.cllc.2011.03.007" @default.
• W1968314925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21550559" @default.
• W1968314925 hasPublicationYear "2011" @default.
• W1968314925 type Work @default.
• W1968314925 sameAs 1968314925 @default.
• W1968314925 citedByCount "24" @default.
• W1968314925 countsByYear W19683149252012 @default.
• W1968314925 countsByYear W19683149252013 @default.
• W1968314925 countsByYear W19683149252014 @default.
• W1968314925 countsByYear W19683149252015 @default.
• W1968314925 countsByYear W19683149252016 @default.
• W1968314925 countsByYear W19683149252017 @default.
• W1968314925 countsByYear W19683149252018 @default.
• W1968314925 countsByYear W19683149252019 @default.
• W1968314925 countsByYear W19683149252020 @default.
• W1968314925 countsByYear W19683149252022 @default.
• W1968314925 countsByYear W19683149252023 @default.
• W1968314925 crossrefType "journal-article" @default.
• W1968314925 hasAuthorship W1968314925A5004625690 @default.
• W1968314925 hasAuthorship W1968314925A5051894582 @default.
• W1968314925 hasAuthorship W1968314925A5052233371 @default.
• W1968314925 hasAuthorship W1968314925A5059111432 @default.
• W1968314925 hasAuthorship W1968314925A5063411006 @default.
• W1968314925 hasAuthorship W1968314925A5064716632 @default.
• W1968314925 hasAuthorship W1968314925A5066993165 @default.
• W1968314925 hasAuthorship W1968314925A5090256464 @default.
• W1968314925 hasConcept C121608353 @default.
• W1968314925 hasConcept C126322002 @default.
• W1968314925 hasConcept C141071460 @default.
• W1968314925 hasConcept C207103383 @default.
• W1968314925 hasConcept C2776256026 @default.
• W1968314925 hasConcept C2776467144 @default.
• W1968314925 hasConcept C2776907518 @default.
• W1968314925 hasConcept C2781413609 @default.
• W1968314925 hasConcept C44249647 @default.
• W1968314925 hasConcept C509974204 @default.
• W1968314925 hasConcept C71924100 @default.
• W1968314925 hasConcept C90924648 @default.
• W1968314925 hasConceptScore W1968314925C121608353 @default.
• W1968314925 hasConceptScore W1968314925C126322002 @default.
• W1968314925 hasConceptScore W1968314925C141071460 @default.
• W1968314925 hasConceptScore W1968314925C207103383 @default.
• W1968314925 hasConceptScore W1968314925C2776256026 @default.
• W1968314925 hasConceptScore W1968314925C2776467144 @default.
• W1968314925 hasConceptScore W1968314925C2776907518 @default.
• W1968314925 hasConceptScore W1968314925C2781413609 @default.
• W1968314925 hasConceptScore W1968314925C44249647 @default.
• W1968314925 hasConceptScore W1968314925C509974204 @default.
• W1968314925 hasConceptScore W1968314925C71924100 @default.
• W1968314925 hasConceptScore W1968314925C90924648 @default.
• W1968314925 hasIssue "2" @default.

• next